Live-cell Kinase Assays
ACD's Tyrosine Kinase Cell-Based Assay
Largest Commercially Available 93 Tyrosine Kinase Cell-Based Panel
|93 Tyrosine Kinases|
|ALK||EphA3||FGFR3 [K650M]||HER3 (ERBB3)||RET|
|ARG (ABL2)||EphA4||FGFR3/BAIAP2L1||IGF1R||RET [V804M]|
|EGFR||FGFR1 [V561M]||FLT3-ITD [D835V]||KIT[D816V]||TIE1|
|FGFR2 [K660E]||FLT3-ITD [F691L]||KIT[N822H]||TRKA (NTRK1)|
|EGFR [L858R]||FGFR2 [K660N]||FLT3-ITD [Y842C]||KIT[T670I]||TRKB (NTRK2)|
|FGFR2 [N550K]||FLT3-ITD [Y842H]||KIT[V654A]||TRKC (NTRK3)|
- Why ACD?
- Comparative Cell-Based Analysis
- To Discover Direct Inhibitory Activity To Targeted Kinases
- Ready-To-Run 93 Tyrosine Kinase (TK) Panel
- Time & Cost Saving Solution for Your In-house Cellular Assays
The assay principle is based on the methods reportedby Daley & Baltimore (1988)* and Jonathan S.Melnick et al.(2005)**. In this cell-based assay, IL3-dependent Ba/F3 cells are transformed by transfection of an human recombinant kinase gene and in turn the modified cells are dependent on the activity of the recombinant kinase for survival and proliferation. For more details of method, please click here.
Please select your target from above 93 tyrosine kinases. The % inhibition or IC50 value determination studies will be performed with your compounds. The validation study with the clinically-relevant kinase inhibitors reveals that this profiling results are consisted with those reported by others.
* Daley and Baltimore; Proc. Natl. Acad. Sci. USA. 1988; 85(23):9312-6
** Melnick et al., pnas.0511292103
% Inhibition & IC50 Detemination Studies
For the % inhibition study, please select at least two concentrations you prefer (10uM maximum). For the IC50 determination study, eight concentrations will be tested in half-log dilutions from the starting concentration you prefer (10uM maximum). The test results will be returned within 4 weeks after a receipt of compounds.
Advanced Cellular Dynamics (San Diego, CA USA) is a leading provider of cell-based assay panel technologies and services to the life-sciences community. ACD develops and deploys families of cell-based screening assays, encompassing broad representations of important target gene families. Their assays are designed to simplify high-throughput screening and profiling of chemical entities in a physiologically relevant cellular environment.